J Korean Acad Child Adolesc Psychiatry.
2012 Oct;23(Suppl):S24-S45.
Safety and Tolerability of OROS Methylphenidate for the Treatment of ADHD
- Affiliations
-
- 1Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- 2Department of Psychiatry, Incheon Christian Hospital, Incheon, Korea.
- 3Department of Psychiatry, Chonbuk National University School of Medicine, Jeonju, Korea.
- 4Department of Psychiatry, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
- 5Department of Psychiatry, Inha University College of Medicine, Incheon, Korea.
- 6Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Korea.
- 7Department of Psychiatry, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea.
- 8Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, Korea.
- 9Department of Psychiatry, Kyung Hee University School of Medicine, Seoul, Korea. mompeian@yahoo.co.kr
Abstract
- We review the effect of methylphenidate, focusing on Osmotic-controlled Release Oral delivery System (OROS) methylphenidate, on cardiovascular system, appetite and growth, sleep, tic, epilepsy, psychiatric and rare adverse events. Although OROS methylphenidate has side effects including increased heart rate or blood pressure, decreased appetite, delayed sleep onset, emergence or aggravation of tics, withdrawal or changes in mood, these effects appeared to be minimal in impact or difficult to distinguish from risk to untreated population and tended to be improved by dose adjustment or drug discontinuation. However, in subjects with underlying cardiac problems, uncontrolled epilepsy, previous psychotic episode, clinicians should pay attention and balance the risk and benefit.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Brief Replication Study Comparing Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder Treatment with a Focus on the Compliance, Efficacy, and Satisfaction
- OROS Methylphenidate Treatment of Secondary Adult ADHD after Traumatic Brain Injury
- Efficacy of OROS Methylphenidate for the Treatment of ADHD
- Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study
- Efficacy and Tolerability of Osmotic Release Oral System-Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder According to Comorbid Psychiatric Disorders
